Gene therapy solutions
When people are born with certain gene mutations, they may not be able to produce proteins that are important for brain development, leading to neurodevelopmental disorders such as Fragile X Syndrome and Dravet Syndrome. Using rodent models of these human genetic disorders, our laboratory is exploring the use of adeno-associated viruses (AAVs) as a way to deliver genes into the brain, with the goal of restoring healthy neuron functioning.
The Hampson Lab
Dr. David R. Hampson is a Professor in the Department of Pharmaceutical Sciences, Faculty of Pharmacy, and the Department of Pharmacology, Faculty of Medicine at the University of Toronto. He specializes in gene therapy and neuroscience. His lab includes members with diverse expertise who are working together to devise novel gene therapy treatments for neurodevelopmental disorders.
(2022) Dr. Hampson has been awarded a new grant from the Canadian Institutes of Health Research to pursue additional research on gene therapy for Dravet Syndrome.
RDMM Network & Dravet Canada Grants
(2021) David Hampson receives
grant from The Rare Diseases Models and Mechanisms Network, and Dravet Canada,
to work on gene therapy for Dravet Syndrome involving mutations in the SCN1B
Taysha Gene Therapies Agreement
(2020) David R. Hampson signs agreement with Taysha Gene Therapies to pursue additional research on gene therapy for treating Fragile X Syndrome.